LAG3 and B-cell chronic lymphocytic leukemia: Therefore, LAG-3 was found to be expressed both on T and malignant B cells in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), especially in Richter transformation (RT), and had a negative impact on progression-free survival (PFS) and overall survival (OS) in DLBC [35,36].